Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
aducanumab
advances in neurology
adverse drug reaction
Alzheimer's disease
Alzheimer's disease, early onset
Alzheimer's disease, pathogenesis
Alzheimer's disease, treatment of
amyloid
amyloid angiopathy, cerebral
amyloid angiopathy, cerebral, inflammatory type
amyloid beta protein
amyloid beta protein antibodies
amyloid beta-related angiitis
amyloid deposition
amyloid plaques
amyloid-related imaging abnormalities
angiitis
angiitis, granulomatous of CNS
angiitis, isolated of CNS
anti-amyloid therapy
apolipoprotein E
biologic markers
brain biopsy
CAT scan, emission
CAT scan, emission, abnormal
cerebral cortical atrophy
cerebral edema
cerebral edema, vasogenic
cerebrospinal fluid, elevated protein of
cerebrospinal fluid, oligoclonal IgG in
coma
complications
confusion
contraindications
controversies in neurology
cost
dementia
dementia, rapidly progressive
dementia, reversible
dementia, treatment of
disease modifying agents
dizziness
donanemab
efficacy
enzyme inhibition
gadolinium
granulomatous disease
headache
hemosiderosis of CNS, superficial
immunomodulation
intracerebral hemorrhage
lecanemab
leukoencephalopathy
memory, impairment of
meningeal biopsy
meningeal enhancement
mental status, abnormal
microhemorrhage, intracerebral
mild cognitive impairment
misdiagnosis
monoclonal antibodies
MRI
MRI, abnormal
MRI, mass effect on
negative
neurologic examination, focal
neuropathology
Pittsburgh Compound B
pleocytosis of cerebrospinal fluid
prevention of neurologic disorders
reversible neurologic disorder
review article
safety
seizure
shared decision making
temporal lobe
tissue plasminogen activator, intravenous
TRAILBLAZER-ALZ trial
transient neurologic deficit
treatment of neurologic disorder
white matter disease
Showing articles 0 to 50 of 1676 Next >>

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023

Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023

Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021

Rapid Progression of Reversible Cognitive Impairment in an 80-year-old Man
Neurol 91:1109-1113, Bouthour, W.,et al, 2018

Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014

Amyloid-Beta Related Angiitis of the Central Nervous System: Case Report and Topic Review
Front Neurol 5:1-4, Nouh, A.,et al, 2014

Anti-Ab Autoantibodies in the CSF of a Patient With CAA-Related Inflammation: A Case Report
Neurol 76:842-844, DiFrancesco,J.C.,et al, 2011

In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009

Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008

Disease-Modifying Therapies for Alzheimers: New Drugs on the Horizon
Practical Neurology 7:16-23, Christensen,D.B., 2008

Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025

A 67 YEar-Old Woman with Progressive Headache, Visual Hallucinations, and Seizures
Neurol 104:e213496, Gheihman,G.,et al, 2025

Sulcal Hyperintensity as an Early Imaging Finding in Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 103:e210084, Panteleienko,L.,et al, 2024

Occult Amyloid-B-Related Angiitis:Neuroimaging Findings at 1.5T, 3T, and 7T MRI
AJNR 45:1013-1018, Ozutemlz,C.,et al, 2024

CSF and Plasma Biomarkers in Patients with Iatrogenic Cerebral Amyloid Angiopathy
Neurol 103:e209828, Pollaci,G.,et al, 2024

Diagnosing Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 103:e209548, Charidimou,A., 2024

Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023

Blook Transfusion and Brain Amyloidosis, Should We Be Worried?
JAMA 330:921-922, Greenberg,S.M., 2023

Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023

Clinical,Neuroimaging,and Genetic Markers in Cerebral Amyloid Angiopatny-Related Inflammation:A Systematic Review and Meta-Analusis
Stroke 54:178-188, Theodorou,A.,et al, 2023

Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022

Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021

Clinicopathologic Conference, Cerebral Amyloid Angiopatny-Related Inflammation
NEJM 385:358-368, Case 22-2021, 2021

Headache, Cognitive Decline, and a Curious Rim-Enhancing Lesion
JAMA Neurol 78:613-614, Beaman, C.B.,et al, 2021

An 81-year-old Woman with Decreased Consciousness and Fluctuating Right Facial Droop
Neurol 94:843-848, Van Ommeren, R.,et al, 2020

Clinicopathologic Conference, AA Amyloidosis, Complicated by Cerebral Mucormycosis
NEJM 382:1457-1466, Case 11-2020, 2020

A 73-Year-Old Man with Recurrent Aphasia, Headaches, and Confusion
Neurol 95:e2595-e2599, Bose, G.,et al, 2020

Acute Convexity Subarachnoid Hemorrhage
Neurol 93:e524-e525, Theodorou, A.,et al, 2019

Cerebral Microbleeds
Neurol 92:e253-e262, Graff-Radford, J.,et al, 2019

�-Amyloid in CSF
Neurol 88:169-176, van Etten, E.Sl.,et al, 2017

Cerebral Amyloid Angiopathy-Related Inflammation Presenting with Isolated Leptomeningitis
Neurol 89:e66-e67, Kang, P.,et al, 2017

Imaging Findings of Cerebral Amyloid Angiopathy A�-Related Angiitis (ABRA), and Cerebral Amyloid Angiopathy-Related Inflammation
Medicine 95:e3613, Salvarani, C.,et al, 2016

Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016

Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation
JAMA Neurol 73:197-202, Auriel, E.,et al, 2016

Pseudotumoral Presentation of Cerebral Amyloid Angiopathy-Related Inflammation
Neurol 86:912-919, Ronsin, S.,et al, 2016

A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016

Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015

Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Inflammatory Cerebral Amyloid Angiopathy, Amyloid-B-Related Angiitis, and Primary Angiitis of the Central Nervous System
Stroke 46:e210-e213, Moussaddy, A.,et al, 2015

Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014

Amyloid Beta-Related Angiitis - A Case Report and Comprehensive Review of Literature of 94 Cases
Semin Arthritis Rheum 44:86-92, Danve, A.,et al, 2014

Predicting Alzheimer Disease with �-Amyloid Imaging: Results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing
Ann Neurol 74:905-913, Rowe, C.C.,et al, 2013

PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013

Inflammatory Cerebral Amyloid Angiopathy and Amyloid-Modifying Therapies: Variations on the Same ARIA?
Ann Neurol 73:439-441, Werring, D. J. & Sperling, R., 2013

Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012

�-Amyloid Burden in Healthy Aging
Neurol 78:387-395, Rodrigue,K.M.,et al, 2012

Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012

Predicting sites of New Hemorrhage with Amyloid Imaging in Cerebral Amyloid Angiopathy
Neurol 79:320-326, Gurol, M.E.,et al, 2012



Showing articles 0 to 50 of 1676 Next >>